Product Description
Demeclocycline is a semisynthetic tetracycline derived from Streptococcus aureofaciens that is used as an antibiotic, but perhaps more frequently as an inhibitor of arginine vasopressin in the therapy of hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK548848/)
Mechanisms of Action: 30S Ribosomal Subunit Inhibitor, Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intramuscular, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Brazil | Canada | Colombia | Dominican Republic | Ecuador | France | Greece | Hong Kong | India | Ireland | Italy | Malta | Mexico | New Zealand | Pakistan | Peru | Taiwan | Thailand | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/10/2019 |
News Article |
Global $268.12 Bn Active Pharmaceutical Ingredient (API) Market to 2026 by Type of Synthesis (Biotech, Synthetic) & Type of Manufacturer (Captive, Merchant) |